CVS will soon cover Eli Lilly's GLP-1 medications, including Foundayo and Zepbound, potentially providing access to these drugs for millions more Americans.

Eli Lilly has projected its 2026 revenue to be between $82 billion and $85 billion, with non-GAAP earnings per share estimated at $35.50 to $37. These projections come as the company begins the launch of its new product, Foundayo.

Analysts remain bullish on Eli Lilly ahead of its Q1 earnings report, with particular focus on the company's obesity drug portfolio and the drug Foundayo. The preview suggests strong performance expectations driven by these key areas.

An article advises investors not to be concerned about the prospects of Eli Lilly (LLY) and Company's Foundayo treatment, implying positive outlooks for the drug.

An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.

Eli Lilly (LLY) has received FDA approval for its new weight management pill, Foundayo, marking a significant development in the treatment of obesity.

Research suggests that both the gut microbiome and Lilly's drug Foundayo can play a role in mitigating the "yo-yo diet" effect, where individuals regain lost weight. This indicates potential new avenues for weight management strategies.

Shares of pharmaceutical company Eli Lilly are under pressure following a report of a serious adverse event related to its drug, Foundayo.

Eli Lilly's stock experienced a decline following a challenging week for its drug Foundayo, while the FDA announced plans to issue vouchers to accelerate research into psychedelic-based medicines.

Eli Lilly's new drug, Foundayo, achieved 1,390 prescriptions during its first week on the market, according to a Reuters report.

In a late-stage trial involving over 2,700 adults, patients taking Lilly's obesity pill Foundayo showed a 16% lower risk of heart attack, stroke, or cardiovascular death.

Eli Lilly's new GLP-1 weight-loss pill, Foundayo, which is the first oral GLP-1 not requiring fasting, has been approved by the Food and Drug Administration and has shown effectiveness in clinical trials, with one user losing 25 pounds.

Wolfe Research suggests that the market's reaction to Eli Lilly's (LLY) Foundayo report appears to be excessive, indicating a potential overcorrection in the stock price.

Lilly's new oral weight loss pill, Foundayo, has shown strong early adoption, surpassing 5600 prescriptions in its third week on the market. This indicates a significant demand for the new pharmaceutical product.

Investors in Eli Lilly are keenly awaiting further information and insights regarding the drug Foundayo, following the release of its early launch data.

New obesity medications, Foundayo and Wegovy, are soon to be available in the UAE, prompting discussions about whether health insurance will cover their costs.

The UAE has become one of the first countries to approve Eli Lilly's once-daily oral obesity pill, Foundayo (orforglipron), a GLP-1 receptor agonist that mimics natural hormones to regulate appetite.

The FDA has granted approval for a new oral weight loss pill named Foundayo, with details released on its usage and implications.